No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery

Background Serotonin–norepinephrine reuptake inhibitors inhibit the reuptake of serotonin and noradrenalin and are used in the treatment of neuropathic pain. Animal studies suggest that milnacipran co‐administered with opioids may potentiate the analgesic effect of μ‐opioid receptor agonists. This s...

Ausführliche Beschreibung